Skip to main content
logo
REYON Pharmaceutical Co., Ltd. (KRX:102460)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,040
-50 (-0.50%)
Sep 11, 2026, 3:30 PM KST

REYON Pharmaceutical Cash Flow Statement

Millions KRW. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-34,245-29,6334,1513,5837,4345,537
Depreciation & Amortization
31,95231,7946,3444,7824,5344,666
Loss (Gain) From Sale of Assets
17.241.8439.08-1.68-24.41140.92
Loss (Gain) From Sale of Investments
-1,008-935.89-387.542,453-4,262-1,125
Loss (Gain) on Equity Investments
-1,885-1,6884,359960.181,968-1,684
Provision & Write-off of Bad Debts
14.5919.6424.63-63.38-79.34467.28
Other Operating Activities
7,666-4,279-17,529-439.2-1,7491,895
Change in Accounts Receivable
1,4662,3183,2261,947-1,134-986.61
Change in Inventory
-1,5064,061-3,470-5,067-3,6772,005
Change in Accounts Payable
1,936-1,3621,8073,39461.52563.61
Change in Income Taxes
----342.94--
Change in Other Net Operating Assets
1,8141,1600.96-1,7814,460199.4
Operating Cash Flow
6,2221,457-1,4368,6458,72911,685
Operating Cash Flow Growth
----0.96%-25.29%154.04%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-5,045-7,916-16,012-28,870-63,133-116,978
Sale of Property, Plant & Equipment
0.820.82-1.7242.278
Sale (Purchase) of Intangibles
820120488.93-2.5--18.7
Investment in Securities
-500-493.96-1,08119,97910,5662,076
Other Investing Activities
52.9951.6113152.12-38.93231.1
Investing Cash Flow
-4,671-7,337-16,591-8,739-52,564-114,682

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Short-Term Debt Issued
-12,0003,000--3,500
Long-Term Debt Issued
--85,00013,100113,900150,100
Total Debt Issued
11,46012,00088,00013,100113,900153,600
Long-Term Debt Repaid
--9,637-81,121-2,205-116,104-2,475
Total Debt Repaid
-14,599-9,637-81,121-2,205-116,104-2,475
Net Debt Issued (Repaid)
-3,1392,3636,87910,895-2,204151,125
Issuance of Common Stock
-----10,000
Repurchase of Common Stock
------76.31
Dividends Paid
---2,751-2,738-4,563-3,464
Other Financing Activities
---0-3.83--9.23
Financing Cash Flow
-3,1392,3634,1288,153-6,767157,576

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-23.05-24.580.21-1.28-89.04-34
Miscellaneous Cash Flow Adjustments
-0-0--0-0-0
Net Cash Flow
-1,611-3,542-13,8988,058-50,69154,544

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,178-6,459-17,448-20,225-54,404-105,293
Free Cash Flow Growth
------
Free Cash Flow Margin
0.82%-4.43%-11.77%-13.39%-35.32%-73.73%
Free Cash Flow Per Share
64.20-352.15-951.29-1102.71-2979.96-5942.30
Levered Free Cash Flow
2,807-15,6017,306-25,600-61,372-109,157
Unlevered Free Cash Flow
11,407-7,3448,089-25,477-61,296-109,087

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
6,4536,6598,478195.52124.0293.37
Cash Income Tax Paid
--191.951,315950.651,188-1,488
Change in Working Capital
3,7106,1771,563-1,851-290.361,782